… However, despite high hopes, most patients with poor PS treated with immunotherapy will
… clinicians will continue to struggle with the difficult choice of immunotherapy versus hospice. …

… of the disease as a result of immunotherapy). In this Review, … immunotherapy. We review
the different types of clinical responses associated with immunotherapy and describe treatment …

… The MaRCC Registry gives insights into real-world first-line treatment selection, outcomes,
and physician rationale regarding initial treatment selection prior to the immunotherapy era. …

… , paving the way for future effective immunotherapy. We systematically reviewed articles from
… and immunotherapy and outline pathways to future personalised therapy of gastric cancer. …

… In the era of personalized treatment, the sampling of adequate tumor tissue for histologic …
The initial molecular pattern must guide the choice of better first-line treatment. In the absence …

… Management of irAEs comprises the temporary or definitive discontinuation of the
immunotherapy and introduction of immunomodulatory therapy, namely GCs as first-line choice (…

… Multivariate logistic regressions were used to evaluate association between patient and
disease characteristics and treatment choice of CT as 1L therapy. The following covariates were …

… Before the introduction and widespread use of single agent immunotherapy as standard
second line choice, combination strategies showed interesting results compared with …

… immunotherapy. Then, we summarize the characteristics of tumor-associated immunity and
immunotherapeutic … as the standard of choice to investigate whether a patient will respond to …

… for the choice of primary treatments, despite presenting several limitations in the current
immunotherapy-era. Multiple predictors of response to immunotherapy or targeted therapies are …